It has been about a month since the last earnings report for Repligen (RGEN) . Shares have added about 3.2% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Repligen due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Repligen’s Q3 Earnings & Revenues Surpass EstimatesRe ...

Core Insights - Repligen Corporation has published its 2023 Corporate Sustainability Report themed "Advancing Impacts," highlighting progress in sustainability across six key areas [1][2] - The report includes disclosures aligned with major reporting frameworks such as GRI, SASB, UN SDGs, and TCFD [1] Sustainability Highlights - Transitioned to 100% renewable electricity at 13 out of 18 manufacturing sites, accounting for 88% of global consumption [3] - Increased the percentage of women in management roles from 27% in 2022 to 29% in 2023 [3] - Achieved a 68% reduction in Scope 2 emissions from 2022 to 2023 [3] - Realized a 60% increase in productivity savings through the Repligen Performance System compared to 2022 [3] - Committed to achieving net-zero emissions by 2050 in alignment with the Science Based Targets initiative [3]

Repligen Corporation (NASDAQ:RGEN) Q3 2024 Results Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Sondra Newman - Vice President, Global Head of Investor Relations Olivier Loeillot - President and Chief Executive Officer Jason Garland - Chief Financial Officer Conference Call Participants Dan Leonard - UBS Dan Arias - Stifel Rachel Vatnsdal - J.P. Morgan Puneet Souda - Leerink Partners Matt Larew - William Blair & Company Jacob Johnson - Stephens Inc. Conor McNamara - RBC Capital ...

Repligen Corporation (RGEN) reported third-quarter 2024 adjusted earnings per share of 43 cents, which beat the Zacks Consensus Estimate of 34 cents. The company recorded adjusted earnings of 23 cents per share in the year-ago quarter.Total revenues were $154.9 million, up 10% year over year on a reported basis. Excluding the impact of acquisition revenues and currency exchange, revenues rose 7% organically. The reported figure also beat the Zacks Consensus Estimate of $153.1 million.This increase in total ...

Repligen Corp RGEN released on Tuesday third-quarter adjusted EPS of 43 cents, up from 23 cents a year ago, beating the consensus of 33 cents.The bioprocessing technology reported sales of $154.87 million, up 10% year-over-year, beating the consensus of $153.23 million.Olivier Loeillot, president and CEO of Repligen, said, "I'm pleased to report strong third-quarter results, made possible by the excellent execution by our team and improving market conditions. We are encouraged to see strengthening CDMO and ...

Repligen (RGEN) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.23 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 26.47%. A quarter ago, it was expected that this drug developer would post earnings of $0.33 per share when it actually produced earnings of $0.33, delivering no surprise.Over the last four quarters, the company has surpa ...

WALTHAM, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at three upcoming investor conferences. The UBS Global Healthcare Conference being held November 11-14 in Rancho Palos Verdes, CA. Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion on Thursday, November 14, at 10:15 a.m. ET.The Stifel Healthcare Conference being held Novembe ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Repligen (RGEN) reports results for the quarter ended September 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the stock may m ...

Dublin, Oct. 14, 2024 (GLOBE NEWSWIRE) -- The "Peptide Therapeutics - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Peptide Therapeutics was estimated at US$42.1 Billion in 2023 and is projected to reach US$56.2 Billion by 2030, growing at a CAGR of 4.2% from 2023 to 2030. The development of peptide therapeutics has been greatly accelerated by technological advances, enabling the creation of more stable, potent, and targeted therapies. Peptides, ...

Core Insights - Repligen Corporation has opened the Repligen Training & Innovation Center (RTIC) at its Waltham headquarters to enhance customer engagement and support [1][3] - The RTIC showcases a comprehensive range of Repligen's bioprocessing technologies, including upstream and downstream products, and serves as a hands-on training facility [2][3] - The company is committed to innovation and aims to meet growing customer expectations in the biologics market as it anticipates a return to growth by 2025 [3] Company Developments - The RTIC spans approximately 7,500 square feet within a 55,000 square foot expansion project, which took 20 months to complete [3] - Repligen has also expanded its presence in Europe with a new 80,000 square foot facility in Jüri, Estonia, which serves as a Customer Center of Excellence [4] - The Estonia facility is LEED Silver certified and supports various functions including R&D, engineering, manufacturing, and technical support [4] Product and Technology Focus - The RTIC features a variety of Repligen's bioprocessing technologies, including XCell® ATF, KrosFlo® TFDF® devices, OPUS® pre-packed chromatography columns, and Spectrum® hollow fiber filters [2] - The center will also highlight process analytics technologies such as CTech™ SoloVPE® and FlowVPX® [2] - Repligen's focus areas include Filtration and Fluid Management, Chromatography, Process Analytics, and Proteins, catering primarily to biopharmaceutical developers and CDMOs [5]